The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Do Lithium and Anticonvulsants Target the Brain Arachidonic Acid Cascade in Bipolar Disorder?
Abstract
BACKGROUND: Lithium and certain anticonvulsants, including carbamazepine and valproic acid, are effective antimanic drugs for treating bipolar disorder, but their mechanisms of action remain uncertain. EXPERIMENTAL OBSERVATIONS: Feeding rats lithium chloride for 6 weeks, to produce a brain lithium concentration of 0.7mM, reduced arachidonic acid turnover within brain phospholipids by 75%. The effect was highly specific, as turnover rates of docosahexaenoic acid and palmitic acid were unaffected. Arachidonate turnover in rat brain also was reduced by long-term valproic acid administration. Lithium's reduction of arachidonate turnover corresponded to its down-regulating gene expression and enzyme activity of cytosolic phospholipase A(2), an enzyme that selectively liberates arachidonic but not docosahexaenoic acid from phospholipids. Lithium also reduced the brain protein level and activity of cyclooxygenase 2, as well as the brain concentration of prostaglandin E(2), an arachidonate metabolite produced via cyclooxygenase 2. CONCLUSIONS: These results give rise to the hypothesis that lithium and antimanic anticonvulsants act by targeting parts of the "arachidonic acid cascade," which may be functionally hyperactive in mania. Thus, drugs that target enzymes in the cascade, such as cyclooxygenase 2 inhibitors, might be candidate treatments for mania. Also, in view of competition between arachidonic and docosahexaenoic acids in a number of functional processes, docosahexaenoic acid or its precursors would be expected to be therapeutic. Neither of these predictions is evident from other current hypotheses for the antimanic action of lithium and anticonvulsant drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Omega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder
Frank, E., Swartz, H. A., & Kupfer, D. J. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00969-0 · Cited by 521
Cited by
Omega-3 fatty acids in major depressive disorder
Su, K.-P., Huang, S.-Y., Chiu, C.-C., & Shen, W. W. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)00032-4 · Cited by 596
Goldstein, B. I., Carnethon, M. R., Matthews, K. A., McIntyre, R. S., Miller, G. E., Raghuveer, G., Stoney, C. M., Wasiak, H., & McCrindle, B. W. (2015) · Circulation · doi:10.1161/cir.0000000000000229 · Cited by 519
Electroconvulsive Seizures Regulate Gene Expression of Distinct Neurotrophic Signaling Pathways
Altar, C. A., Laeng, P., Jurata, L. W., Brockman, J. A., Lemire, A., Bullard, J., Bukhman, Y. V., Young, T. A., Charles, V., & Palfreyman, M. G. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5377-03.2004 · Cited by 317
Su, K.-P., Huang, S.-Y., Chiu, T.-H., Huang, K.-C., Huang, C.-L., Chang, H.-C., & Pariante, C. M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0418 · Cited by 308
Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview
Mazza, M., Pomponi, M., Janiri, L., Bria, P., & Mazza, S. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.07.010 · Cited by 306
Rosenberg, G. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7079-x · Cited by 300
The role of dopamine in bipolar disorder
Cousins, D. A., Butts, K., & Young, A. H. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00760.x · Cited by 291
Inhibition of GSK3 by lithium, from single molecules to signaling networks
Freland, L., & Beaulieu, J.-M. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00014 · Cited by 269
Immune variations in bipolar disorder: phasic differences
Ortiz‐Domínguez, A., Hernández, M. E., Berlanga, C., Gutiérrez‐Mora, D., Moreno, J., Heinze, G., & Pavón, L. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00493.x · Cited by 255
Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00005 · Cited by 229
Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications
Mcintyre, R., Konarski, J., Misener, V., & Kennedy, S. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230590932380 · Cited by 203
Guo, J.-Y., Li, C.-Y., Ruan, Y.-P., Sun, M., Qi, X.-L., Zhao, B.-S., & Luo, F. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.076 · Cited by 148
Omega-3 fatty acids and the treatment of depression: a review of scientific evidence
Wani, A. L., Bhat, S. A., & Ara, A. (2015) · Integrative Medicine Research · doi:10.1016/j.imr.2015.07.003 · Cited by 97
Ghelardoni, S., Tomita, Y. A., Bell, J. M., Rapoport, S. I., & Bosetti, F. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.05.012 · Cited by 95
Self-citationAcetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats
Wang, Y., Yang, F., Liu, Y.-F., Gao, F., & Jiang, W. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.05.035 · Cited by 56
Rapoport, S. I., & Hibbeln, J. R. (2020) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102118 · Cited by 11
Self-citation
Metadata
- Authors
- Rapoport, S. I., & Bosetti, F.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-01
- Volume
- 59
- Issue
- 7
- Pages
- 592
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W1971118360
- Cited by
- 188
- References
- 2
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.